Lamivudine Therapy in Kidney Allograft Recipients Who Are Seropositive for Hepatitis B Surface Antigen

Filik, Levent; Karakayalı, H.; Moray, Gökhan; Dalgic, A.; Emiroğlu, R; Özdemir, Nurhan; Çolak, Turan; Yılmaz, Uğur; Haberal, Mehmet

doi:10.1016/j.transproceed.2005.12.047

Cited by 25 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Resistance rates across the trials were significant at 18% after median treatment duration of 18 months. Studies evaluating the benefits of prophylactic lamivudine versus treatment only on reactivation suggest that with the latter approach the majority of patients will end up on treatment (Chan et al, 2002) and may have a worse outcome than those treated prophylactically (Filik et al, 2006).…”

Section: Management Post Transplant-antiviral Therapymentioning

confidence: 99%

The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting

Barclay

Pol

Mutimer

et al. 2008

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Management Post Transplant-antiviral Therapymentioning

confidence: 99%

The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting

Barclay

Pol

Mutimer

et al. 2008

Journal of Clinical Virology

View full text Add to dashboard Cite

“…HBeAg positivity was variable ranging from 17–100% patients while in our study it was 77%. In five studies[14172527–28] liver enzyme status at the time of starting lamivudine was not available, while in the remaining studies, ALT was elevated in most of the patients. Liver biopsy findings were not available in eight studies.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and tolerability of lamivudine in hepatitis B infected renal transplant recipients: A single center study

Agarwal¹,

Sc²

2009

Indian J Nephrol

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection in patients on hemodialysis and renal transplantation (RT) usually has an unfavorable course. Lamivudine is a synthetic nucleoside analog with a potent action on HBV replication. There is limited data on lamivudine in renal transplant patients with HBV infection and no published report from India. Present study reports on lamivudine therapy in these patients. Patients with HBV infection taken for RT were included. Hepatitis B surface antigen (HBsAg), hepatitis B envelope antigen (HBeAg), HBV-DNA, and liver biopsy before RT were done in all patients. Lamivudine was given in the dose of 50 mg daily during the dialysis and 100 mg daily following successful transplant. Response was evaluated at one year. Of the 739 adult RTs during study period, 35 (4.7%) had HBV infection. Mean age of patients was 30.7 ± 9.8 (16–55 years) and 88.5% were males. Four (11.4%) patients had HCV coinfection. HCV was not treated in any patient. All patients were HBsAg and HBV-DNA positive, while 27 (77%) were HBeAg positive. Mean ALT was 77.8 ± 90 IU/dl; 11 (31.4%) patients had normal ALT. Mean liver biopsy grade was 5.2 ± 1.5 (3–9) and stage was 0.7 ± 0.6 (0–2). At one year following transplantation, ALT was normal in 27 (77%) cases, HBV-DNA undetectable in 16 (45.7%), HBeAg and HBsAg seroconversion in 8 (22.8%), and 3 (8.6%) cases, respectively. All patients tolerated the drug without any significant side effects. Treatment with lamivudine in dialysis and renal transplant patients is well tolerated and safe with efficacy comparable to patients with normal renal function.

show abstract

“…In a small study, LAM given as either prophylactic or preemptive treatment was proven superior to salvage therapy when liver dysfunction is evident [51] . None of the HBsAg positive patients receiving prophylactic or pre-emptive therapy developed reactivation, while 50% of the patients not been treated suffered reactivation [51,52] . These results were confirmed by others, but there is some controversy about the clinical impact of prophylactic/preemptive therapy vs salvage therapy [51][52][53][54][55] .…”

Section: Ridruejo E Nuc Treatment In Rt Patientsmentioning

confidence: 94%

“…None of the HBsAg positive patients receiving prophylactic or pre-emptive therapy developed reactivation, while 50% of the patients not been treated suffered reactivation [51,52] . These results were confirmed by others, but there is some controversy about the clinical impact of prophylactic/preemptive therapy vs salvage therapy [51][52][53][54][55] . One study showed that there was no differences in survival between HBsAg positive RT patients treated preemptively with LAM and HBsAg negative controls.…”

Section: Ridruejo E Nuc Treatment In Rt Patientsmentioning

confidence: 94%

Antiviral treatment for chronic hepatitis B in renal transplant patients

Ridruejo

2014

WJH

View full text Add to dashboard Cite

Chronic hepatitis B infection is frequent in renal transplant patients. It negatively impacts long term outcomes reducing graft and patient survival. Current guidelines clearly define who needs treatment, when to start, what is the first line therapy, how to monitor treatment response, when to stop, and how patients must be controlled for its safety. There is some data showing a favorable safety and efficacy profile of nucleos(t)ide analogue (NUC) treatment in the renal transplant setting. Entecavir, a drug without major signs of nephrotoxicity, appears to be the first option for NUC naïve patients and tenofovir remains the preferred choice for patients with previous resistance to lamivudine or any other NUC. Renal transplant recipients under antiHBV therapy should be monitored for its efficacy against HBV but also for its safety with a close renal monitoring. Studies including a large number of patients with long term treatment and follow up are still needed to better demonstrate the safety and efficacy of newer NUCs in this population. Core tip: Nucleos(t)ide analogue treatment is safe and effective in renal transplant patients. It improves long term patients and graft survival.Ridruejo E. Antiviral treatment for chronic hepatitis B in renal transplant patients.

show abstract

Lamivudine Therapy in Kidney Allograft Recipients Who Are Seropositive for Hepatitis B Surface Antigen

Cited by 25 publications

References 11 publications

The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting

The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting

Efficacy and tolerability of lamivudine in hepatitis B infected renal transplant recipients: A single center study

Antiviral treatment for chronic hepatitis B in renal transplant patients

Contact Info

Product

Resources

About